These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 5430846)

  • 21. [Prolonged use of atromid in patients with coronary arteriosclerosis].
    Zadionchenko VS
    Kardiologiia; 1967 Oct; 7(10):32-5. PubMed ID: 5607197
    [No Abstract]   [Full Text] [Related]  

  • 22. [Clinical evaluation of the therapeutic activity of the -pyridyl-carbinol ester of clofibric acid].
    Silingardi V; Renzi R; Mora A; Di Prisco AU
    Minerva Med; 1973 Mar; 64(16):751-69. PubMed ID: 4704721
    [No Abstract]   [Full Text] [Related]  

  • 23. Prevention and regression of atherosclerosis with drug therapy.
    Superko HR
    Clin Cardiol; 1991 Feb; 14(2 Suppl 1):I40-7. PubMed ID: 2044258
    [No Abstract]   [Full Text] [Related]  

  • 24. [Clinical experimental lipid metabolism studies with essential phospholipids taking into account the arteriosclerosis problem].
    Hammerl H; Pichler O; Studlar M
    Wien Med Wochenschr; 1966 Apr; 116(16):348-52. PubMed ID: 5985190
    [No Abstract]   [Full Text] [Related]  

  • 25. Clofibrate and androsterone effect on serum lipids.
    Orgain ES; Bogdonoff MD; Cain C
    Arch Intern Med; 1967 Jan; 119(1):80-5. PubMed ID: 6015838
    [No Abstract]   [Full Text] [Related]  

  • 26. [Effect of nerobol on the contractile capacity of the myocardium].
    Beĭ PI
    Klin Med (Mosk); 1972 Jan; 50(1):69-74. PubMed ID: 5020033
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical prevention of coronary heart disease through cholesterol-lowering therapy.
    Grundy SM
    Curr Ther Endocrinol Metab; 1997; 6():520-6. PubMed ID: 9174799
    [No Abstract]   [Full Text] [Related]  

  • 28. What kinds of studies should be required to probe efficacy and safety of drugs in special populations?
    LaRosa JC; Sneider GB; Boyle C
    Am J Cardiol; 1998 Apr; 81(8A):84F-87F. PubMed ID: 9604921
    [No Abstract]   [Full Text] [Related]  

  • 29. [Treatment of atherosclerosis with hypolipidemic and antiuricemic agents].
    Plastinina RA; Oleĭnik NA; Valeeva RM; Pavlova TN
    Sov Med; 1984; (1):83-7. PubMed ID: 6701660
    [No Abstract]   [Full Text] [Related]  

  • 30. [Clinico-experimental studies of the influence of Atherolip on lipid and carbohydrate metabolism].
    Hammerl H; Kränzl C; Pichler O; Studlar M
    Med Welt; 1969 Aug; 31():1715-7. PubMed ID: 4895455
    [No Abstract]   [Full Text] [Related]  

  • 31. Warfarin metabolism during ethyl chlorophenoxyisobutyrate treatment.
    Pyörälä K; Ristola P; Myllylä G
    Ann Med Intern Fenn; 1968; 57(4):157-60. PubMed ID: 5731345
    [No Abstract]   [Full Text] [Related]  

  • 32. [Currently used therapeutic agents for arteriosclerosis--with special reference to a protein anabolic hormone, clofibrate (C.P.I.B.)].
    Yasugi T; Sasa E
    Nihon Rinsho; 1970 May; 28(5):1470-4. PubMed ID: 4915308
    [No Abstract]   [Full Text] [Related]  

  • 33. [Nicotinic acid and the derivative].
    Ogaki S; Matsushima T
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():637-41. PubMed ID: 11347146
    [No Abstract]   [Full Text] [Related]  

  • 34. [Hypolipemic effects of a new tetralin derivative: compound 13473-Su (Ciba)].
    Ciobanu V; Zălaru MC; Ciocan A; Mihăilescu S
    Stud Cercet Med Interna; 1971; 12(1):67-80. PubMed ID: 5565781
    [No Abstract]   [Full Text] [Related]  

  • 35. [Currently used therapeutic agents for arteriosclerosis--with special reference ro a protein anabolic hormone, clofibrate (C.P.I.B.)].
    Yasugi T; Sasa E
    Nihon Rinsho; 1970 May; 28(5):1470-4. PubMed ID: 4916330
    [No Abstract]   [Full Text] [Related]  

  • 36. [The drug therapy of hypercholesterolemia].
    Berthold HK; von Bergmann K
    Dtsch Med Wochenschr; 1996 May; 121(22):729-34. PubMed ID: 8646985
    [No Abstract]   [Full Text] [Related]  

  • 37. Rational prescribing of statins.
    Purcell H; Daly C; Sheppard M; Morrell J
    Practitioner; 2001 Nov; 245(1628):957-9, 962-3. PubMed ID: 11727350
    [No Abstract]   [Full Text] [Related]  

  • 38. [Therapeutic effects of furazabol, (17-beta-hydroxy-17-alpha-methyl-5-alpha-androstane [2, 3-c] furazan, on experimental atherosclerosis in rabbits].
    Onodera T; Kasahara A; Ishihara M; Ogawa H; Oshima Y
    Nihon Yakurigaku Zasshi; 1970 Jul; 66(4):458-69. PubMed ID: 5531414
    [No Abstract]   [Full Text] [Related]  

  • 39. The influence of Clofibrat on plasma lipid levels.
    Szostak WB; Cybulska B; Ruzyllo E
    Mater Med Pol; 1971; 3(4):12-4. PubMed ID: 5162168
    [No Abstract]   [Full Text] [Related]  

  • 40. [Changes in the plasma concentration of some lipid fractions in patients treated with arterial wall extract].
    Natale L
    Clin Ter; 1974 Jul; 70(1):17-62. PubMed ID: 4408827
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.